First Wave BioPharma Shares Fall 45% After FW-COV Results, Workforce Reduction News

- Advertisement -


By Stephen Nakrosis

- Advertisement -
- Advertisement -

Shares of biopharmaceutical company First Wave BioPharma Inc. were lower in Friday’s late session, after the company’s Chairman, President and Chief Executive, James Sapirstein, said in a letter to shareholders the company would reduce headcount and initiate austerity measures to conserve capital.

The company’s decision follows data from the Phase 2 RESERVOIR trial examining the safety and efficacy of FW-COV as a potential treatment for Covid-19-related GI infections. Mr. Sapirstein said top-line data from the trial were mixed.

- Advertisement -

Along with a 20% reduction in headcount, the company will close its West Coast office and a facility in Langlade, France. First Wave also intends to defer certain obligations, including payment obligations related to the acquisition of First Wave Bio Inc., Mr. Sapirstein said.

At 4:46 pm ET, the company’s shares were trading 45.
buy elavil online salempregnancy.org/wp-content/languages/new/elavil.html no prescription

16% lower, at 34 cents per share. The stock finished the day’s regular session with a 3.16% loss, closing at 62 cents a share.

The stock touched a 52-week low of 60 cents per share on Thursday.

Write to Stephen Nakrosis at [email protected]

,

Credit: www.marketwatch.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox